Anti-MET Antibody (MetY12341235-6F11) APC BHA10600076

The Mesenchymal Epithelial Transition (MET) receptor belongs to a family of receptor tyrosine kinases (RTKs). Dyregulation of the MET signaling pathway occurs in wide range of human tumors (1,2).  The MET receptor is a glycoprotein heterodimer consisting of an extracellular α-subunit linked to transmembrane β-subunit by a disulfide bond (3).  The MET receptor is widely expressed on the surface of epithelial and endothelial cells.  MET ligand is known as the hepatocyte growth factor (HGF), also called the scatter factor (SF).  HGF/SF is a serine protease and produced in cells of mesenchymal origin. HGF is secreted as a s ingle chain, biologically inactive protein which is further processed into its mature form by a cleavage process catalyzed by extracellular proteases (4-6).  MET and its ligand HGF are involved in several normal and pathological processes, such as fetal liver, placenta and muscle development, as well as development of the nervous system (7-9).  MET signal transduction is involved in tumor growth, invasion, resistance to therapy, angiogenesis and specially in the generation and maintenance of cancer stem cells (CSCs) (10-12).